1
|
Oh HR, Ko MK, Son D, Ki YW, Kim SI, Lee SY, Kang KW, Cheon GJ, Hwang DW, Youn H. Activated Natural Killer Cell Inoculation Alleviates Fibrotic Liver Pathology in a Carbon Tetrachloride-Induced Liver Cirrhosis Mouse Model. Biomedicines 2023; 11:biomedicines11041090. [PMID: 37189708 DOI: 10.3390/biomedicines11041090] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2023] [Revised: 03/23/2023] [Accepted: 03/29/2023] [Indexed: 05/17/2023] Open
Abstract
Activated hepatic stellate cells (HSCs) play a detrimental role in liver fibrosis progression. Natural killer (NK) cells are known to selectively recognize abnormal or transformed cells via their receptor activation and induce target cell apoptosis and, therefore, can be used as a potential therapeutic strategy for liver cirrhosis. In this study, we examined the therapeutic effects of NK cells in the carbon tetrachloride (CCl4)-induced liver cirrhosis mouse model. NK cells were isolated from the mouse spleen and expanded in the cytokine-stimulated culture medium. Natural killer group 2, member D (NKG2D)-positive NK cells were significantly increased after a week of expansion in culture. The intravenous injection of NK cells significantly alleviated liver cirrhosis by reducing collagen deposition, HSC marker activation, and macrophage infiltration. For in vivo imaging, NK cells were isolated from codon-optimized luciferase-expressing transgenic mice. Luciferase-expressing NK cells were expanded, activated and administrated to the mouse model to track them. Bioluminescence images showed increased accumulation of the intravenously inoculated NK cells in the cirrhotic liver of the recipient mouse. In addition, we conducted QuantSeq 3' mRNA sequencing-based transcriptomic analysis. From the transcriptomic analysis, 33 downregulated genes in the extracellular matrix (ECM) and 41 downregulated genes involved in the inflammatory response were observed in the NK cell-treated cirrhotic liver tissues from the 1532 differentially expressed genes (DEGs). This result indicated that the repetitive administration of NK cells alleviated the pathology of liver fibrosis in the CCl4-induced liver cirrhosis mouse model via anti-fibrotic and anti-inflammatory mechanisms. Taken together, our research demonstrated that NK cells could have therapeutic effects in a CCl4-induced liver cirrhosis mouse model. In particular, it was elucidated that extracellular matrix genes and inflammatory response genes, which were mainly affected after NK cell treatment, could be potential targets.
Collapse
Affiliation(s)
- Ho Rim Oh
- Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul 03080, Republic of Korea
- Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul 03080, Republic of Korea
- Cancer Research Institute, Seoul National University College of Medicine, Seoul 03080, Republic of Korea
| | - Min Kyung Ko
- Research & Development Center, THERABEST, Co., Ltd., Seoul 06656, Republic of Korea
| | - Daehee Son
- Research & Development Center, THERABEST, Co., Ltd., Seoul 06656, Republic of Korea
| | - Young Wook Ki
- Research & Development Center, THERABEST, Co., Ltd., Seoul 06656, Republic of Korea
| | - Shin-Il Kim
- Research & Development Center, THERABEST, Co., Ltd., Seoul 06656, Republic of Korea
| | - Seok-Yong Lee
- Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul 03080, Republic of Korea
- Cancer Research Institute, Seoul National University College of Medicine, Seoul 03080, Republic of Korea
- Cancer Imaging Center, Seoul National University Hospital, Seoul 03080, Republic of Korea
| | - Keon Wook Kang
- Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul 03080, Republic of Korea
- Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul 03080, Republic of Korea
- Cancer Research Institute, Seoul National University College of Medicine, Seoul 03080, Republic of Korea
| | - Gi Jeong Cheon
- Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul 03080, Republic of Korea
- Cancer Research Institute, Seoul National University College of Medicine, Seoul 03080, Republic of Korea
| | - Do Won Hwang
- Research & Development Center, THERABEST, Co., Ltd., Seoul 06656, Republic of Korea
| | - Hyewon Youn
- Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul 03080, Republic of Korea
- Cancer Research Institute, Seoul National University College of Medicine, Seoul 03080, Republic of Korea
- Cancer Imaging Center, Seoul National University Hospital, Seoul 03080, Republic of Korea
| |
Collapse
|
9
|
Becker AS, Perez-Johnston R, Chikarmane SA, Chen MM, El Homsi M, Feigin KN, Gallagher KM, Hanna EY, Hicks M, Ilica AT, Mayer EL, Shinagare AB, Yeh R, Mayerhoefer ME, Hricak H, Vargas HA. Multidisciplinary Recommendations Regarding Post-Vaccine Adenopathy and Radiologic Imaging: Radiology Scientific Expert Panel. Radiology 2021; 300:E323-E327. [PMID: 33625298 PMCID: PMC7909071 DOI: 10.1148/radiol.2021210436] [Citation(s) in RCA: 81] [Impact Index Per Article: 27.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
Vaccination-associated adenopathy is a frequent imaging finding after administration of COVID-19 vaccines that may lead to a diagnostic conundrum in patients with manifest or suspected cancer, in whom it may be indistinguishable from malignant nodal involvement. To help the medical community address this concern in the absence of studies and evidence-based guidelines, this special report offers recommendations developed by a multidisciplinary panel of experts from three of the leading tertiary care cancer centers in the United States. According to these recommendations, some routine imaging examinations, such as those for screening, should be scheduled before or at least 6 weeks after the final vaccination dose to allow for any reactive adenopathy to resolve. However, there should be no delay of other clinically indicated imaging (eg, for acute symptoms, short-interval treatment monitoring, urgent treatment planning or complications) due to prior vaccination. The vaccine should be administered on the side contralateral to the primary or suspected cancer, and both doses should be administered in the same arm. Vaccination information-date(s) administered, injection site(s), laterality, and type of vaccine-should be included in every preimaging patient questionnaire, and this information should be made readily available to interpreting radiologists. Clear and effective communication between patients, radiologists, referring physician teams, and the general public should be considered of the highest priority when managing adenopathy in the setting of COVID-19 vaccination.
Collapse
Affiliation(s)
- Anton S Becker
- From the Department of Radiology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, Room H-704, New York, NY 10065 (A.S.B., R.P.J., M.E.H., K.N.F., K.M.G., A.T.I., R.Y., M.E.M., H.H., H.A.V.); Department of Radiology, Brigham and Women's Hospital, Boston, Mass (S.A.C., A.B.S.); Departments of Imaging (S.A.C., A.B.S.) and Medical Oncology (E.L.M.), Dana-Farber Cancer Institute, Boston, Mass; and Division of Diagnostic Imaging (M.M.C., M.H.) and Department of Head and Neck Surgery (E.Y.H.), MD Anderson Cancer Center, Houston, Tex
| | - Rocio Perez-Johnston
- From the Department of Radiology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, Room H-704, New York, NY 10065 (A.S.B., R.P.J., M.E.H., K.N.F., K.M.G., A.T.I., R.Y., M.E.M., H.H., H.A.V.); Department of Radiology, Brigham and Women's Hospital, Boston, Mass (S.A.C., A.B.S.); Departments of Imaging (S.A.C., A.B.S.) and Medical Oncology (E.L.M.), Dana-Farber Cancer Institute, Boston, Mass; and Division of Diagnostic Imaging (M.M.C., M.H.) and Department of Head and Neck Surgery (E.Y.H.), MD Anderson Cancer Center, Houston, Tex
| | - Sona A Chikarmane
- From the Department of Radiology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, Room H-704, New York, NY 10065 (A.S.B., R.P.J., M.E.H., K.N.F., K.M.G., A.T.I., R.Y., M.E.M., H.H., H.A.V.); Department of Radiology, Brigham and Women's Hospital, Boston, Mass (S.A.C., A.B.S.); Departments of Imaging (S.A.C., A.B.S.) and Medical Oncology (E.L.M.), Dana-Farber Cancer Institute, Boston, Mass; and Division of Diagnostic Imaging (M.M.C., M.H.) and Department of Head and Neck Surgery (E.Y.H.), MD Anderson Cancer Center, Houston, Tex
| | - Melissa M Chen
- From the Department of Radiology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, Room H-704, New York, NY 10065 (A.S.B., R.P.J., M.E.H., K.N.F., K.M.G., A.T.I., R.Y., M.E.M., H.H., H.A.V.); Department of Radiology, Brigham and Women's Hospital, Boston, Mass (S.A.C., A.B.S.); Departments of Imaging (S.A.C., A.B.S.) and Medical Oncology (E.L.M.), Dana-Farber Cancer Institute, Boston, Mass; and Division of Diagnostic Imaging (M.M.C., M.H.) and Department of Head and Neck Surgery (E.Y.H.), MD Anderson Cancer Center, Houston, Tex
| | - Maria El Homsi
- From the Department of Radiology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, Room H-704, New York, NY 10065 (A.S.B., R.P.J., M.E.H., K.N.F., K.M.G., A.T.I., R.Y., M.E.M., H.H., H.A.V.); Department of Radiology, Brigham and Women's Hospital, Boston, Mass (S.A.C., A.B.S.); Departments of Imaging (S.A.C., A.B.S.) and Medical Oncology (E.L.M.), Dana-Farber Cancer Institute, Boston, Mass; and Division of Diagnostic Imaging (M.M.C., M.H.) and Department of Head and Neck Surgery (E.Y.H.), MD Anderson Cancer Center, Houston, Tex
| | - Kimberly N Feigin
- From the Department of Radiology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, Room H-704, New York, NY 10065 (A.S.B., R.P.J., M.E.H., K.N.F., K.M.G., A.T.I., R.Y., M.E.M., H.H., H.A.V.); Department of Radiology, Brigham and Women's Hospital, Boston, Mass (S.A.C., A.B.S.); Departments of Imaging (S.A.C., A.B.S.) and Medical Oncology (E.L.M.), Dana-Farber Cancer Institute, Boston, Mass; and Division of Diagnostic Imaging (M.M.C., M.H.) and Department of Head and Neck Surgery (E.Y.H.), MD Anderson Cancer Center, Houston, Tex
| | - Katherine M Gallagher
- From the Department of Radiology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, Room H-704, New York, NY 10065 (A.S.B., R.P.J., M.E.H., K.N.F., K.M.G., A.T.I., R.Y., M.E.M., H.H., H.A.V.); Department of Radiology, Brigham and Women's Hospital, Boston, Mass (S.A.C., A.B.S.); Departments of Imaging (S.A.C., A.B.S.) and Medical Oncology (E.L.M.), Dana-Farber Cancer Institute, Boston, Mass; and Division of Diagnostic Imaging (M.M.C., M.H.) and Department of Head and Neck Surgery (E.Y.H.), MD Anderson Cancer Center, Houston, Tex
| | - Ehab Y Hanna
- From the Department of Radiology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, Room H-704, New York, NY 10065 (A.S.B., R.P.J., M.E.H., K.N.F., K.M.G., A.T.I., R.Y., M.E.M., H.H., H.A.V.); Department of Radiology, Brigham and Women's Hospital, Boston, Mass (S.A.C., A.B.S.); Departments of Imaging (S.A.C., A.B.S.) and Medical Oncology (E.L.M.), Dana-Farber Cancer Institute, Boston, Mass; and Division of Diagnostic Imaging (M.M.C., M.H.) and Department of Head and Neck Surgery (E.Y.H.), MD Anderson Cancer Center, Houston, Tex
| | - Marshall Hicks
- From the Department of Radiology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, Room H-704, New York, NY 10065 (A.S.B., R.P.J., M.E.H., K.N.F., K.M.G., A.T.I., R.Y., M.E.M., H.H., H.A.V.); Department of Radiology, Brigham and Women's Hospital, Boston, Mass (S.A.C., A.B.S.); Departments of Imaging (S.A.C., A.B.S.) and Medical Oncology (E.L.M.), Dana-Farber Cancer Institute, Boston, Mass; and Division of Diagnostic Imaging (M.M.C., M.H.) and Department of Head and Neck Surgery (E.Y.H.), MD Anderson Cancer Center, Houston, Tex
| | - Ahmet T Ilica
- From the Department of Radiology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, Room H-704, New York, NY 10065 (A.S.B., R.P.J., M.E.H., K.N.F., K.M.G., A.T.I., R.Y., M.E.M., H.H., H.A.V.); Department of Radiology, Brigham and Women's Hospital, Boston, Mass (S.A.C., A.B.S.); Departments of Imaging (S.A.C., A.B.S.) and Medical Oncology (E.L.M.), Dana-Farber Cancer Institute, Boston, Mass; and Division of Diagnostic Imaging (M.M.C., M.H.) and Department of Head and Neck Surgery (E.Y.H.), MD Anderson Cancer Center, Houston, Tex
| | - Erica L Mayer
- From the Department of Radiology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, Room H-704, New York, NY 10065 (A.S.B., R.P.J., M.E.H., K.N.F., K.M.G., A.T.I., R.Y., M.E.M., H.H., H.A.V.); Department of Radiology, Brigham and Women's Hospital, Boston, Mass (S.A.C., A.B.S.); Departments of Imaging (S.A.C., A.B.S.) and Medical Oncology (E.L.M.), Dana-Farber Cancer Institute, Boston, Mass; and Division of Diagnostic Imaging (M.M.C., M.H.) and Department of Head and Neck Surgery (E.Y.H.), MD Anderson Cancer Center, Houston, Tex
| | - Atul B Shinagare
- From the Department of Radiology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, Room H-704, New York, NY 10065 (A.S.B., R.P.J., M.E.H., K.N.F., K.M.G., A.T.I., R.Y., M.E.M., H.H., H.A.V.); Department of Radiology, Brigham and Women's Hospital, Boston, Mass (S.A.C., A.B.S.); Departments of Imaging (S.A.C., A.B.S.) and Medical Oncology (E.L.M.), Dana-Farber Cancer Institute, Boston, Mass; and Division of Diagnostic Imaging (M.M.C., M.H.) and Department of Head and Neck Surgery (E.Y.H.), MD Anderson Cancer Center, Houston, Tex
| | - Randy Yeh
- From the Department of Radiology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, Room H-704, New York, NY 10065 (A.S.B., R.P.J., M.E.H., K.N.F., K.M.G., A.T.I., R.Y., M.E.M., H.H., H.A.V.); Department of Radiology, Brigham and Women's Hospital, Boston, Mass (S.A.C., A.B.S.); Departments of Imaging (S.A.C., A.B.S.) and Medical Oncology (E.L.M.), Dana-Farber Cancer Institute, Boston, Mass; and Division of Diagnostic Imaging (M.M.C., M.H.) and Department of Head and Neck Surgery (E.Y.H.), MD Anderson Cancer Center, Houston, Tex
| | - Marius E Mayerhoefer
- From the Department of Radiology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, Room H-704, New York, NY 10065 (A.S.B., R.P.J., M.E.H., K.N.F., K.M.G., A.T.I., R.Y., M.E.M., H.H., H.A.V.); Department of Radiology, Brigham and Women's Hospital, Boston, Mass (S.A.C., A.B.S.); Departments of Imaging (S.A.C., A.B.S.) and Medical Oncology (E.L.M.), Dana-Farber Cancer Institute, Boston, Mass; and Division of Diagnostic Imaging (M.M.C., M.H.) and Department of Head and Neck Surgery (E.Y.H.), MD Anderson Cancer Center, Houston, Tex
| | - Hedvig Hricak
- From the Department of Radiology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, Room H-704, New York, NY 10065 (A.S.B., R.P.J., M.E.H., K.N.F., K.M.G., A.T.I., R.Y., M.E.M., H.H., H.A.V.); Department of Radiology, Brigham and Women's Hospital, Boston, Mass (S.A.C., A.B.S.); Departments of Imaging (S.A.C., A.B.S.) and Medical Oncology (E.L.M.), Dana-Farber Cancer Institute, Boston, Mass; and Division of Diagnostic Imaging (M.M.C., M.H.) and Department of Head and Neck Surgery (E.Y.H.), MD Anderson Cancer Center, Houston, Tex
| | - H Alberto Vargas
- From the Department of Radiology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, Room H-704, New York, NY 10065 (A.S.B., R.P.J., M.E.H., K.N.F., K.M.G., A.T.I., R.Y., M.E.M., H.H., H.A.V.); Department of Radiology, Brigham and Women's Hospital, Boston, Mass (S.A.C., A.B.S.); Departments of Imaging (S.A.C., A.B.S.) and Medical Oncology (E.L.M.), Dana-Farber Cancer Institute, Boston, Mass; and Division of Diagnostic Imaging (M.M.C., M.H.) and Department of Head and Neck Surgery (E.Y.H.), MD Anderson Cancer Center, Houston, Tex
| |
Collapse
|